Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
07 Settembre 2022 - 2:30PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage
biopharmaceutical company developing products to improve the
survival and/or quality of life for patients who have an unmet
medical need condition today announced that Dr. Dr. David Young,
Chief Executive Officer, will present at the H.C. Wainwright
22nd Annual Global Investment Conference on Wednesday,
September 14, 2022.
A live webcast of Dr. Youngs presentation will
be available in the investor relations section on the Company’s
website and at the following link:
https://journey.ct.events/view/6fe806c7-abc0-4d17-ae78-a6bcaf52c5cf
About Processa Pharmaceuticals,
Inc.
The mission of Processa is to develop products
with existing clinical evidence of efficacy for patients with unmet
or underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company uses these
criteria for selection to further develop its pipeline programs to
achieve high-value milestones effectively and efficiently. Active
clinical pipeline programs include: PCS6422 (metastatic colorectal
cancer and breast cancer), PCS499 (ulcerative necrobiosis
lipoidica) and PCS12852 (GI motility/gastroparesis). Members of the
Processa development team have been involved with more than 30 drug
approvals by the FDA (including drug products targeted to orphan
disease conditions) and more than 100 FDA meetings throughout their
careers. For more information, visit our website
at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:Michael
Floydmfloyd@processapharma.com(301) 651-4256
Patrick Lin(925)
683-3218plin@processapharma.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024